Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol

Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high quality evidence of benefit. However there remains uncertainty as to whether these benefits apply at higher gestational ages.The...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC Pregnancy and Childbirth 2013-04, Vol.13 (1), p.91-91, Article 91
Hauptverfasser:	Crowther, Caroline A, Middleton, Philippa F, Wilkinson, Dominic, Ashwood, Pat, Haslam, Ross
Format:	Artikel
Sprache:	eng
Schlagworte:	Blindness - etiology Blindness - prevention & control Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - therapeutic use Cerebral palsy Cerebral Palsy - etiology Cerebral Palsy - prevention & control Child Behavior Child, Preschool Chlorides Comparative analysis Deafness - etiology Deafness - prevention & control Developmental Disabilities - etiology Developmental Disabilities - prevention & control Dichloropropane Ethical aspects Female Gestational Age Health aspects Health Status Humans Infant Infant Mortality Infant, Newborn Infant, Premature Infant, Premature, Diseases - prevention & control Infants (Premature) Magnesium sulfate Magnesium Sulfate - administration & dosage Magnesium Sulfate - therapeutic use Nutritional aspects Observational studies Perinatal Mortality Pregnancy Pregnant women Premature babies Premature birth Premature Birth - drug therapy Premature Birth - mortality Psychological Tests Research Design Risk factors Stillbirth Study Protocol Systematic review Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!